Designing fisetin nanocrystals for enhanced in cellulo anti-angiogenic and anticancer efficacy

We report the formulation, characterization, colloidal stability, and in vitro efficiency of Fisetin nanocrystals stabilized by poloxamer P407. Such nanocrystals present a nanometer scale (148.6 +/- 1.1 nm) and a high homogeneity (polydispersity index of 0.17 +/- 0.01), with a production yield of 97.0 +/- 2.5%. The engineered formulations of nanocrystals suspension (pH of 7.4 +/- 0.1), stabilized via steric repulsion, are stable for several days in aqueous environment (Milli Q water, NaCl 10 mM or mannitol 5% w/v), for few days in HEPES buffered saline (HBS) (20 / 150 mM) under sink conditions, and in culture medium. After freeze drying in 5% w/v mannitol, the nanocrystal formulations can be stored at -80 degrees C for at least 120 days. Drug release experiments displayed a 98.7 +/- 5.1% cumulative release over 3 days in HBS. Compared to the free drug, the nanocrystal formulations showed an improved cytotoxicity highlighted by the decrease of the half maximal inhibitory concentration for both murine Lewis lung carcinoma (3LL) and human endothelial (EA.hy926) cell lines. In addition, after incubation with Fisetin nanosuspensions, significant changes in the cell morphology for both cell lines were observed, showing an improved anti-angiogenic effect of nanocrystals formulation compared to the free drug. Overall, Fisetin formulated as nanocrystals showed enhanced biopharmaceutical properties and in vitro activity, offering a wide range of indications for challenging applications in the clinic.

Automated summary

This study reports the formulation, stability, and in vitro efficiency of Fisetin nanocrystals stabilized by poloxamer P407. The nanocrystals exhibit uniform size and high stability in various environments, and show improved cytotoxicity and anti-angiogenic effect compared to the free drug, suggesting promising clinical applications.